In summary, current data support the idea that FGF21 acts directly on cardiac tissue to prevent the development of cardiac hypertrophy, reduce infarct damage, and attenuate the development of diabetic cardiomyopathy in animal models. Here, FGF21 is linked to cardiac hypertrophy.